Return on Assets (ROA): Ginkgo Bioworks Holdings's ROA lags behind industry averages, suggesting challenges in maximizing ...

Ginkgo Bioworks Holdings, Inc. (DNA) ended the recent trading session at $8.27, demonstrating a +1.35% swing from the preceding day's closing price. The stock outpaced the S&P 500's daily gain of 0.27 ...

Ginkgo Bioworks has been busy, announcing not just one but three acquisitions and the creation of a network backed by 25 partners that will offer ‘end-to-end’ services to R&D clients.

Presentation and Q&A session scheduled for post-market on Tuesday, November 12, 2024 The presentation details and webcast link will be available on Ginkgo's investor relations website at https ...

Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.63 in the latest trading session, marking a -1.55% move from the prior day.

In this article, we are going to take a look at where Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) stands against other most promising gene editing stocks to buy according to hedge funds. The ...

Ginkgo Bioworks Holdings Inc, based in Boston, Massachusetts, specializes in cell programming to revolutionize the production of various products. By manipulating cells, they create novel ...

Ginkgo Bioworks had a negative net margin of 486.98% and a negative return on equity of 63.09%. On average, sell-side analysts expect that Ginkgo Bioworks Holdings, Inc. will post -12.6 earnings ...

BOSTON, Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BOSTON, Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading ...